Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
Risk of fracture among patients with rheumatoid arthritis according to serological status: a population-based retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Seonghye, Han Kyung-Do, Jung Jinhyung, Cho Hyeonjin, Kang Seonyoung, Kim Hyungjin, Cho In Young, Shin Dong Wook
Аннотация
UNLABELLED: Patients with rheumatoid arthritis have higher fracture risks than those without RA, particularly in seropositive cases. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further large-scale studies. Our findings highlight the need for active surveillance and timely intervention in RA patients, particularly those with SPRA and regardless of bDMARD or tsDMARD use.
OBJECTIVES: Evidence of the association between the serological status and the risk of fracture among patients with rheumatoid arthritis (RA) considering exposure to disease-modifying antirheumatic drugs (DMARDs) is scarce. We investigated the risk of fracture among patients with RA according to the serological status considering exposures to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).
METHODS: We conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database including patients who were diagnosed with RA between 2010 and 2017 (n = 43,677) and controls matched according to age and sex (n = 131,031).
RESULTS: Patients with RA had a higher risk of any fractures compared to matched controls (adjusted hazard ratio [aHR] 1.68, 95% confidence interval [CI] 1.62‒1.75). Patients with seropositive RA (SPRA) had an increased risk of fracture (aHR 1.19, 95% CI 1.11‒1.28 for any fractures; aHR 1.40, 95% CI 1.26‒1.55 for vertebral fractures; aHR 1.55, 95% CI 1.19‒2.02 for hip fractures) compared to those with seronegative RA. Compared to matched controls, RA patients showed higher fracture risk regardless of bDMARDs (exposed: 2.28-fold; unexposed: 1.64-fold) or tsDMARDs (exposed: 1.91-fold; unexposed: 1.68-fold).
CONCLUSION: Patients with RA were at higher risk of fractures compared to those without RA, with even higher risk among those with SPRA. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further studies to explore the impact of bDMARDs and tsDMARDs on fracture risk in patients with RA.
OBJECTIVES: Evidence of the association between the serological status and the risk of fracture among patients with rheumatoid arthritis (RA) considering exposure to disease-modifying antirheumatic drugs (DMARDs) is scarce. We investigated the risk of fracture among patients with RA according to the serological status considering exposures to biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).
METHODS: We conducted a population-based retrospective cohort study using the Korean National Health Insurance Service database including patients who were diagnosed with RA between 2010 and 2017 (n = 43,677) and controls matched according to age and sex (n = 131,031).
RESULTS: Patients with RA had a higher risk of any fractures compared to matched controls (adjusted hazard ratio [aHR] 1.68, 95% confidence interval [CI] 1.62‒1.75). Patients with seropositive RA (SPRA) had an increased risk of fracture (aHR 1.19, 95% CI 1.11‒1.28 for any fractures; aHR 1.40, 95% CI 1.26‒1.55 for vertebral fractures; aHR 1.55, 95% CI 1.19‒2.02 for hip fractures) compared to those with seronegative RA. Compared to matched controls, RA patients showed higher fracture risk regardless of bDMARDs (exposed: 2.28-fold; unexposed: 1.64-fold) or tsDMARDs (exposed: 1.91-fold; unexposed: 1.68-fold).
CONCLUSION: Patients with RA were at higher risk of fractures compared to those without RA, with even higher risk among those with SPRA. The risk of fractures remained elevated regardless of bDMARD or tsDMARD use, warranting further studies to explore the impact of bDMARDs and tsDMARDs on fracture risk in patients with RA.